Related Experiment Video
Updated: Oct 14, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
Michel El Khoury1, Boutros Karam2, Rabih Tabet2
1Internal Medicine, Staten Island University Hospital - Northwell Health, New York City, USA.
Insights
Patients with bleeding disorders face complex cardiovascular care. Managing acute coronary syndromes requires tailored antithrombotic and factor replacement therapies to balance bleeding and clotting risks.
Area of Science:
- Cardiology
- Hematology
- Interventional Cardiology
Background:
- Acute coronary artery disease (CAD) is a leading global cause of death.
- Coagulation disorders may offer protection against ischemic heart disease, but atherosclerotic lesions are observed in hemophilia patients.
- Increased life expectancy in patients with bleeding disorders leads to a higher incidence of cardiovascular diseases, complicating treatment.
Purpose of the Study:
- To review the challenges and strategies for managing acute coronary syndromes in patients with coagulation disorders.
- To highlight the need for individualized treatment approaches balancing antithrombotic and factor replacement therapies.
- To emphasize early screening and intervention for cardiovascular risk factors in this population.
Main Methods:
- Review of current literature and clinical practices for managing acute coronary syndromes (STEMI, NSTEMI, unstable angina) in patients with bleeding disorders.
- Discussion of interventional strategies, including stent selection and vascular access.
- Analysis of anticoagulation and antiplatelet therapy considerations, including prophylactic factor replacement.
Main Results:
- ST-elevation myocardial infarction (STEMI) requires prompt percutaneous coronary intervention (PCI), while non-STEMI (NSTEMI) and unstable angina necessitate hematology consultation.
- Newer drug-eluting stents may be safe with limited dual antiplatelet therapy (DAPT) duration (4 weeks) in high bleeding risk patients.
- Radial artery access is preferred over femoral access due to lower bleeding risk. Heparin is a preferred anticoagulant due to its short half-life and available antidote.
Conclusions:
- Managing acute coronary syndromes in patients with coagulation disorders requires careful, individualized antithrombotic and factor replacement strategies.
- Close peri-procedural monitoring and patient education on bleeding symptoms are crucial.
- Early screening for cardiovascular risk factors and timely intervention can improve outcomes and reduce morbidity in this population.
Abstract:
Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

